OxTalks Change Freeze Starts 2 March
Oxford Events, the new replacement for OxTalks, will launch on 16th March. The two-week OxTalks freeze period starts on Monday 2nd March. During this time, there will be no facility to publish or edit events. The existing OxTalks site will remain available to view during this period. Once Oxford Events launches, you will need a Halo login to submit events. Full details are available on the Staff Gateway.
Clinical applications of 7T MRI: epilepsy, mitochondrial disease, glioblastoma and heart failure
Ultra-high field (7T+) MRI is emerging from being a topic of interest to MRI physicists into a genuinely clinical imaging modality. 7T offers exquisite sub-millimetre spatial resolution and sensitivity to subtle changes in tissue contrast. Yet conventional single transmit 7T MRI was hampered by signal voids that often obscure significant parts of the brain, which is clearly unacceptable for diagnostic imaging when the locus of disease is unknown. New parallel transmit methods offer high-fidelity whole-brain imaging, which since 2024 is available with UKCA/CE/FDA approvals for diagnostic imaging on Siemens new Terra.X scanners. In this seminar, I describe recent translational clinical studies at Cambridge and the method developments that were needed to facilitate them. These include a study applying parallel transmit 7T MRI for pre-surgical assessment of patients with severe epilepsy whose previous clinical 3T and FDG-PET had been inconclusive. PTx-7T MRI changed clinical management to the benefit of 56% of our first 31 patients. Per lesion detected, it is 10x cheaper than alternative invasive stereotactic EEG investigations, not to mention being safer and more convenient. I am now setting up the world’s first multisite prospective trial of 7T MRI for epilepsy pre-surgical evaluation in collaboration with King’s College London to assess the health economic case for NHS adoption of 7T MRI in epilepsy. Another ongoing study “DefINe” is applying R2* mapping techniques validated in the UK7T Network’s travelling heads study as the primary endpoint for a CTIMP trial evaluating whether the drug deferiprone can be repurposed to treat patients with the rare mitochondrial disease neuroferritinopathy which causes inevitable incurable dementia in the 40s. As well as these 1H-MRI imaging studies, I describe our recent work developing quantitative deuterium metabolic imaging for applicants in cancer and neurodegeneration, and ongoing studies assessing regional cellular energy metabolism by phosphorus MRSI in the heart and brain.
Date:
11 March 2026, 12:00
Venue:
FMRIB Centre, Headington OX3 9DU
Venue Details:
Cowey Room
Speaker:
Chris Rodgers (University of Cambridge)
Organising department:
Nuffield Department of Clinical Neurosciences
Organiser contact email address:
admin@oxcin.ox.ac.uk
Part of:
OxCIN Seminar Series
Booking required?:
Not required
Booking url:
https://www.oxcin.ox.ac.uk/events/mental-navigation-and-the-default-mode-network-from-spatial-maps-to-conceptual-knowledge
Audience:
Members of the University only
Editor:
Iske Bakker
